Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.43 |
| ▸ | ANPEP | P15144 | 6/20 | 0.41 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.41 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.41 |
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.34 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594704 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL1911122 | 1.00 | SLC7A5 (0.56) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL56161 | 0.98 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL56160 | 0.98 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Hydrochloric Acid SCHEMBL3223338 | 0.98 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| Trifluoroacetic Acid SCHEMBL2494882 | 0.87 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL18774975 | 0.80 | SLC7A5 (0.50) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL18774973 | 0.79 | SLC7A5 (0.54) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP | |
| SCHEMBL24049287 | 0.79 | ANPEP (0.45) | SLC7A5ANPEPRNPEPDNPEPMMP1 | |
| SCHEMBL6857551 | 0.79 | SLC7A5 (0.48) | SLC7A5SLC1A3SLC1A2ANPEPRNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771327-B1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | claimed |
| EP-2718266-B9 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | claimed |
| EP-3072886-A1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2016-09-28 | — | — | EP | claimed |
| US-9403808-B2 | Pyrazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2016-08-02 | — | — | US | claimed |
| EP-2718266-B1 | PYRIDIN-2-AMIDES USEFUL AS CB2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-05-25 | — | — | EP | claimed |
| US-9321727-B2 | Pyridine derivatives as agonists of the CB2 receptor | HOFFMANN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | claimed |
| US-9290451-B2 | — | — | 2016-03-22 | — | — | US | claimed |
| EP-2771327-A1 | NOVEL PYRAZINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-03 | — | — | EP | claimed |
| WO-2013060751-A1 | NOVEL PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-02 | — | — | WO | claimed |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | claimed |
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | US | claimed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | MERCK SHARP & DOHME LLC (US) | 2023-06-08 | — | — | US | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| WO-1998007742-A1 | SULFONAMIDES | ZENECA LIMITED (GB) | 1998-02-26 | — | — | WO | disclosed |
| US-4382889-A | Epoxysuccinic acid derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| US-4333879-A | CALCIUM-ACTIVATED NEUTRAL THIOLPROTEASE INHIBITOR USED IN THE TREATMENT OF MUSCULAR DYSTROPHY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316147-A1 | NOVEL PYRIDINE DERIVATIVES | NDUFS6, NDUFS4, NDUFV1 | SLC7A5 2449/4885SLC1A3 2241/4885SLC1A2 1254/4885 |
| US-11679090-B2 | Modulators of Sestrin-GATOR2 interaction and uses thereof | GATD3, GABRR2, GABRR3 | SLC7A5 2349/4885SLC1A3 219/4885SLC1A2 138/4885 |
| US-20130109665-A1 | NOVEL PYRAZINE DERIVATIVES | CNR2, CNR1, GPR174 | SLC7A5 3557/4885SLC1A3 2616/4885SLC1A2 1028/4885 |
| US-20230174567-A1 | SYNTHESIS OF FLUORINATED NUCLEOTIDES | NUDT1, NT5C3B, MTAP | SLC7A5 1279/4885SLC1A3 3464/4885SLC1A2 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.